These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 29332873)

  • 21. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.
    Koh KN; Im HJ; Suh JK; Lee SW; Choi ES; Seo JJ
    Pediatr Blood Cancer; 2015 Jun; 62(6):1063-5. PubMed ID: 25641881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
    Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
    Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
    Angelopoulou MK; Vassilakopoulos TP; Batsis I; Sakellari I; Gkirkas K; Pappa V; Giannoulia P; Apostolidis I; Apostolopoulos C; Roussou P; Panayiotidis P; Dimou M; Kyrtsonis MC; Palassopoulou M; Vassilopoulos G; Moschogiannis M; Kalpadakis C; Margaritis D; Spyridonidis A; Michalis E; Anargyrou K; Repousis P; Hatzimichael E; Bousiou Z; Poulakidas E; Grentzelias D; Harhalakis N; Pangalis GA; Anagnostopoulos A; Tsirigotis P
    Hematol Oncol; 2018 Feb; 36(1):174-181. PubMed ID: 28219112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
    Chen R; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Huebner D; Fong A; Younes A
    Blood; 2016 Sep; 128(12):1562-6. PubMed ID: 27432875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
    Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
    Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
    Dada R; Zekri J; Al Saadi R
    Expert Opin Biol Ther; 2016 Jun; 16(6):739-45. PubMed ID: 27096887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
    Gopal AK; Chen R; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Chi X; Sievers EL; Younes A
    Blood; 2015 Feb; 125(8):1236-43. PubMed ID: 25533035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
    Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
    Chen R; Palmer JM; Thomas SH; Tsai NC; Farol L; Nademanee A; Forman SJ; Gopal AK
    Blood; 2012 Jun; 119(26):6379-81. PubMed ID: 22611160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation.
    Baxley AA; Kumm DE; Bishop CB; Medina PJ; Holter-Chakrabarty J
    J Oncol Pharm Pract; 2013 Sep; 19(3):279-83. PubMed ID: 23154572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.
    Chen R; Palmer JM; Tsai NC; Thomas SH; Siddiqi T; Popplewell L; Farol L; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1864-8. PubMed ID: 25008328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
    Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
    Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature.
    Nagaharu K; Masuya M; Kageyama Y; Yamaguchi T; Ito R; Kawakami K; Ito M; Katayama N
    J Med Case Rep; 2018 May; 12(1):151. PubMed ID: 29843820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
    Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
    Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful Pregnancy and Fetal Outcomes Following Brentuximab Vedotin for Early Relapsed Classic Hodgkin Lymphoma After Autologous Stem Cell Transplant.
    Goto A; Fujita C; Horiguchi H; Iyama S; Kobune M
    Cureus; 2024 Mar; 16(3):e57291. PubMed ID: 38690456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Brentuximab vedotin and cord blood transplantation for primary refractory Hodgkin lymphoma following autologous hematopoietic stem cell transplantation].
    Meshitsuka S; Suzuki K; Igeta Y; Kawai S; Kumasaka T; Tsukada N
    Rinsho Ketsueki; 2015 Jun; 56(6):699-704. PubMed ID: 26256882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.
    Broccoli A; Argnani L; Coppola PE; Gentilini M; Bagnato G; Lolli G; Carella M; Nanni L; Morigi A; Casadei B; Pellegrini C; Stefoni V; Zinzani PL
    Tumori; 2023 Apr; 109(2):249-252. PubMed ID: 35441544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.